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1. Introduction1
Acute myocardial infarction is the heart disease that have 
complicated treatment, high mortality rate, and poor prog-
nosis. Previous treatment mainly target on the specific 
symptoms, treatment for the primary disease and applica-
tion of anticoagulant, however the therapeutic effect was 
less effective. Acute myocardial infarction (AMI) drug 
reperfusion therapy has been used in clinical practice, so 
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that the prognosis of patients with ST segment elevation 
acute myocardial infarction (STEMI) has improved sig-
nificantly. Thrombolytic therapy aimed at the opening the 
lumen of blood vessels to save the necrotic myocardium in 
the treatment of myocardial infarction and was achieved 
good results. It not only significantly reduce the mortality 
of patients, but also greatly improve the quality of life of 
patients. But it is a hot topic in clinical research to reduce 
the injury of ischemia and reperfusion injury. Edaravone is 
a new hydroxy free radical scavenger, during animal test-
ing of myocardial ischemia and perfusion experiments 
the drug prove that can reduce the ischemia-reperfusion 
injury [1]. The theory of edaravone has great potential for 
myocardial ischemia-reperfusion protection. In September 
2012 to September 2013, author studied on patient that 
hospitalized due to myocardial infarction and treated by 
combined ultra-early urokinase and intravenous injection 
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of coronary recanalization increases 1.7 times (p < 0.01), the differences were statistical-
ly significant. Conclusion: For acute myocardial ischemia injection of edaravone before 
reperfusion and combine with pharmacological treatment can alleviate myocardial isch-
emia reperfusion injury, effectively scavenge oxygen free radicals and improve the ability 
of antioxidant. Both improve the thrombolytic treatment and protective effect for acute 
myocardial ischemia were significant. Hence, edaravone can is a kind of new milestone 
in the clinical cardiovascular drugs.
Study on the Protective Effect of Edaravone on 
Myocardial Ischemia Reperfusion Injury
Hui Hou*
Xuanwu Hospital of Capital Medical University, Beijing 100053, China
ORIGINAL ARTICLE
Hui Hou
Volume 2   |   December 2013   |   11Advanced Emergency Medicine
obtain better curative effect.
2. Materials and methods
2.1. Clinical data
This group of patients with myocardial infarction hospital-
ized from September 2012 to September 2013. Standard 
criteria: (1) Age is more than or equal to 18 years old, (2) 
Symptoms of myocardial ischemia continued more than 
or equal to 30 min, (3) AMI symptoms (chest pain) onset 
within 6 hours, (4) Two or more than two limb lead ST 
segment elevation is equal to or more than 0.1 mV or two 
or more adjacent precordial ST segment elevation is equal 
to or larger than 0.2 mV; (5) Required to sign the informed 
consent. Treatment group consist of 41 cases (male 35 cas-
es, female 6 cases), aged 42 to 73 years old and average age 
was 54.2 years old. Control group consist of 39 cases (31 
males and 8 females), aged from 39 to 69 years, with an av-
erage age of 52.2 years.
2.2. Treatment method
Patients after clinically diagnosed and do the appropriate 
checks, to comply with thrombolysis time and signed the 
indications and surgical agreement. After that, immediate-
ly infusion of diluted urokinase with 20,000 U/kg for less 
than 30 min. Subsequently, after the end of thrombolysis 
patient subjected underwent ECG, for determine the effect 
of thrombolysis. After diagnosed, patients in the treatment 
group administrated with edaravone 30 mg (Jiangsu Sim-
cere Pharmaceutical Co., Ltd.) +0.9% normal saline solu-
tion 100 mL by intravenous infusion. After thrombolytic 
therapy with intravenous infusion, same dose of edara-
vone was administrated for 14 days. The control group was 
treated with intravenous drip of placebo. 24 h after throm-
bolysis both group were given low molecular weight hepa-
rin sodium 5000 U subcutaneous injection, QD, for 7 d, 
and control blood pressure [2,4].
2.3. Efficacy evaluation criteria
ECG and hemodynamic monitoring were performed in all 
groups, and the occurrence of reperfusion arrhythmia was 
observed. The coronary CT was determined by the blood 
vessel and the case fatality rate.
2.4. Statistical processing
Data mean + standard deviation said, using the SPSS 11.0 
statistical software, using t test, p < 0.05 significant, p < 0.01 
is extremely significant.
3. Results
Observed and compared the standard of both groups, from 
there ST segment elevation for both group, and the condi-
tion of arrhythmia and infarction angina pectoris was re-
corded in the results. 
ST segment elevation type myocardial infarction after 
thrombolytic therapy of edaravone in treatment group rep-
erfusion rate was 65.5%, besides, data of after reperfusion 
group and no reperfusion group in ST segment elevation, 
arrhythmia and infarction angina occurred rate was com-
pared. Difference was statistically significant (p < 0.01).
The comparison of two groups of arrhythmia shown that 
in treatment group, having frequent ventricular premature 
beat, compared to the control group. There was no signifi-
cant difference (p > 0.05) in the acceleration of ventricular 
arrhythmia, ventricular tachycardia, sinus arrest and ven-
tricular fibrillation, the difference was statistically signifi-
cant (p < 0.01).
In the both groups, the rate of blood vessel and the mor-
tality of 4 weeks, the rate of vascular retreated by CT was 
significantly improved, and the difference was statistically 
significant [3].
4. Discussion
Myocardial infarction is refer to acute, persistent ischemia, 
hypoxia (coronary insufficiency) which caused by myocar-
dial necrosis. Because of the non-regeneration of myocar-
dial cells, the effective and timely opening of blood vessels 
are to achieve reperfusion to save the ischemic myocar-
dium is very important. Only the adequate reperfusion, 
able to rescue the condition, where function of severe isch-
emia myocardial cell able to quickly restore, and provide 
an effective treatment. But not all patients with reperfusion 
can have a good clinical effect. Many cases of reperfusion 
injury will cause AMI extended or severe arrhythmia, and 
resulting in death.
Among all the mechanisms that cause ischemia reperfu-
sion injury, free radical chain reaction [5−7] is considered 
to be one of the important mechanisms in the pathogen-
esis of myocardial tissue damage which caused by ischemia 
reperfusion.  Due to an abnormality of the blood supply, 
through the mitochondria of myocardial cells, xanthine 
oxidase in vascular endothelial cells, neutrophil respiratory 
burst and catecholamine oxidation pathway, these process 
produces a large number of free radicals, which enable the 
biofilm structure damaged, and cause the generation of 
lipid peroxidation, in further releasing large amounts of 
intracellular enzyme, that cause swelling of mitochondria, 
and resulting in dysfunction of myocardial cell. Moreover, 
it resulting in reperfusion arrhythmia, myocardial stun-
ning suppression, apoptosis and necrosis of tissues, and 
microvascular injury. Eventually, cause severe myocardial 
cell necrosis. Cardiac arrhythmia is easy to occur during 
reperfusion, and the occurrence rate is very high. The ECG 
of reperfusion myocardial injury was more than that of ST 
segment after reperfusion, and the elevation of myocardial 
injury was greater. Multiple manifestations of ventricular 
premature contractions in the short-array of ventricular 
tachycardia, acceleration of ventricular arrhythmia and 
late diastolic phase. The emergence of reperfusion arrhyth-
mia is a sensitive indicator of the end stage to save the re-
versible injury of myocardium. Successful reperfusion can 
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occur with fatal reperfusion arrhythmia, which must be at-
tached great importance in the process of thrombolysis. In 
patients with chest pain, the blood pressure decreased and 
arrhythmia, which indicated that reperfusion injury was 
obvious, and the ischemic injury of myocardium was lead 
to irreversible damage. The new injury of reperfusion inju-
ry and the extent of the injury, make the myocardial injury 
become more serious, and affect the improvement of myo-
cardial ischemia, hence it should be paid attention to. A 
large number of experiments and clinical data confirmed 
that inhibition of free radical production and scavenging 
free radical provide protective effect to ischemia reperfu-
sion injury [8−11].
Edaravone is currently the only effective clinical use free 
radical scavenger, the research shows that it scavenging 
harmful hydroxyl radical (OH) and other toxic free radi-
cals produced after reperfusion and provide excellent pro-
tection effect in the treatment of acute myocardial infarc-
tion, at the same time improve the prognosis effect. This 
study found that urokinase thrombolysis combined with 
edaravone can decrease free radical chain reaction after 
urokinase thrombolysis reperfusion of blood flow and pro-
mote the timely removal of free radicals and rescue isch-
emic myocardium. Besides, it reduce serious malignant 
reperfusion arrhythmia, increased coronary recanalization 
rate, and reduce mortality in patients [12−14]. This sug-
gests that importance of timely removal of the free radicals 
in myocardial ischemia and early reperfusion. The com-
bined use of Edaravone and urokinase treatment of myo-
cardial infarction might have synergistic effect, safe and 
effective, and worthy of promotion.
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